Regenerative Medical Technology (RMTG) Accounts Payables (2017 - 2024)
Regenerative Medical Technology (RMTG) posted quarterly Accounts Payables of $1.3 million for Q4 2024, up 201.81% year-over-year from $421334.0 in Q1 2024, and up 15.3% quarter-over-quarter from $1.1 million in Q3 2024.
Regenerative Medical Technology (RMTG) Accounts Payables (2017 - 2024) Analysis & Trends
Regenerative Medical Technology's Accounts Payables history runs 8 years deep, the most recent figure standing at $1.3 million for Q4 2024.
- In Q4 2024, Accounts Payables rose 201.81% year-over-year to $1.3 million; the TTM figure through Dec 2024 stood at $1.3 million (up 201.81% YoY), while the FY2024 annual figure was $1.3 million, up 201.81% from the prior year.
- Accounts Payables for Q4 2024 stood at $1.3 million, up from $1.1 million in the prior quarter.
- The five-year high for Accounts Payables was $1.3 million in Q4 2024, with the low at $81808.0 in Q2 2021.
- The 5-year median for Accounts Payables is $370557.5 (2023), against an average of $416783.9.
- The sharpest annual moves came in 2021 and 2024: Accounts Payables slumped 79.16% in 2021, then surged 201.81% in 2024.
- Regenerative Medical Technology's Accounts Payables stood at $375789.0 in 2020, then tumbled by 51.72% to $181442.0 in 2021, then soared by 35.28% to $245463.0 in 2022, then surged by 71.65% to $421334.0 in 2023, then soared by 201.81% to $1.3 million in 2024.
- Business Quant data shows RMTG's Accounts Payables at $1.3 million in Q4 2024, $1.1 million in Q3 2024, and $562188.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 562,188.00 |
| Mar 31, 2024 | 554,520.00 |
| Dec 31, 2023 | 421,334.00 |
| Sep 30, 2023 | 367,108.00 |
| Jun 30, 2023 | 336,884.00 |
| Mar 31, 2023 | 374,007.00 |
| Dec 31, 2022 | 245,463.00 |
| Sep 30, 2022 | 279,372.00 |
| Jun 30, 2022 | 230,031.00 |
| Mar 31, 2022 | 378,305.00 |
| Dec 31, 2021 | 181,442.00 |
| Sep 30, 2021 | 225,481.00 |
| Jun 30, 2021 | 81,808.00 |
| Mar 31, 2021 | 363,808.00 |
| Dec 31, 2020 | 375,789.00 |
| Sep 30, 2020 | 166,795.00 |
| Jun 30, 2020 | 392,629.00 |
| Mar 31, 2020 | 424,189.00 |